Article
Next-generation flexible formats of VNAR domains expand the drug platform's utility and developability
31 Oct 2018
Abstract excerpt
Therapeutic mAbs have delivered several blockbuster drugs in oncology and autoimmune inflammatory disease. Revenue for mAbs continues to rise, even in the face of competition from a growing portfolio of biosimilars. Despite this success, there are still limitations associated with the use of mAbs as therapeutic molecules. With a molecular mass of 150 kDa, a two-chain structure and complex glycosylation these...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
